SCHEMBL22426504

SCHEMBL22426504

COC(=O)c1ccccc1-c1nc(-c2ccccc2O)c2ccccn12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.46
▸ TSHR P16473 1/20 0.46
▸ MAPT P10636 5/20 0.45
▸ MEN1 O00255 3/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ USP2 O75604 1/20 0.45
▸ IDO1 P14902 4/20 0.44
▸ BAZ2B Q9UIF8 1/20 0.43
▸ BAZ2A Q9UIF9 1/20 0.43
▸ TOP2A P11388 1/20 0.43
▸ HIF1A Q16665 1/20 0.42
▸ EPAS1 Q99814 1/20 0.42
▸ KDM4A O75164 1/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ PPARG P37231 2/20 0.41
▸ NCOR2 Q9Y618 2/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ GPR55 Q9Y2T6 1/20 0.41
▸ THRB P10828 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22426522 0.88 IDO1 (0.48) LMNATSHRMAPTMEN1KMT2A
SCHEMBL22406330 0.85 KDM4A (0.47) LMNAMAPTMEN1KMT2AUSP2
SCHEMBL30369496 0.85 KDM4A (0.47) LMNAMAPTMEN1KMT2AUSP2
SCHEMBL22426353 0.84 MAPT (0.53) LMNAMAPTMEN1KMT2AIDO1
SCHEMBL30369237 0.82 HIF1A (0.47) LMNATSHRMAPTMEN1KMT2A
SCHEMBL22426348 0.82 HIF1A (0.47) LMNATSHRMAPTMEN1KMT2A
SCHEMBL22426428 0.78 HIF1A (0.61) LMNATSHRMEN1KMT2ABAZ2B
SCHEMBL22426205 0.76 MAPT (0.46) LMNAMAPTMEN1KMT2AUSP2
SCHEMBL22426451 0.76 GAA (0.46) TSHRMAPTMEN1KMT2AUSP2
SCHEMBL22426417 0.76 HIF1A (0.43) MAPTMEN1KMT2ABAZ2BBAZ2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3938364-B1 COMPOUNDS FOR AND METHODS OF TREATING DISEASES ALTERITY THERAPEUTICS LTD (AU) 2023-08-23 — — EP disclosed
US-10941143-B2 Imidazo [1,5-a]pyridine compounds and their use Alterity Therapeutics Limited (AU) 2021-03-09 — — US disclosed
WO-2020186291-A1 COMPOUNDS FOR AND METHODS OF TREATING DISEASES Alterity Therapeutics Limited (AU) 2020-09-24 — — WO disclosed
US-20200291021-A1 COMPOUNDS FOR AND METHODS OF TREATING DISEASES Alterity Therapeutics Limited (AU) 2020-09-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10941143-B2 Imidazo [1,5-a]pyridine compounds and their use SNCA, PARK7, HTT LMNA 2264/4885TSHR 2438/4885MAPT 8/4885
US-20200291021-A1 COMPOUNDS FOR AND METHODS OF TREATING DISEASES SNCA, HTT, PARK7 LMNA 1654/4885TSHR 2870/4885MAPT 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback